Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Keywords

ReactogenicityImmunogenicityMedicineTolerabilityVirologyVaccinationPandemicCoronavirusAdverse effectImmunologyCoronavirus disease 2019 (COVID-19)Internal medicinePharmacologyAntibodyDiseaseInfectious disease (medical specialty)

Affiliated Institutions

Related Publications

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti , Katie Ewer , Parvinder K. Aley +97 more

2020 The Lancet 2590 citations

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Evan J. Anderson , Nadine Rouphael , Alicia T. Widge +34 more

In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutra...

2020 New England Journal of Medicine 1581 citations

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Chien‐Te K. Tseng , Elena Sbrana , Naoko Iwata‐Yoshikawa +5 more

These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type i...

2012 PLoS ONE 604 citations

Publication Info

Year: 2020
Type: article
Volume: 586
Issue: 7830
Pages: 589-593
Citations: 1546
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1546

OpenAlex

Cite This

APA Style

                            
                                
                                    Mark J. Mulligan, 
                                
                                    Kirsten E. Lyke, 
                                
                                    Nicholas Kitchin
                                
                                et al.
                            
                            (2020). 
                            Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. 
                            Nature
                            , 586
                            (7830)
                            , 589-593.
                            https://doi.org/10.1038/s41586-020-2639-4
                        

Identifiers

DOI: 10.1038/s41586-020-2639-4